A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Trial Identifier: 7517-CL-0101
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: September 2019
Primary Completion Date: April 2023
Study Completion Date: April 2023
Condition: Heart, Blood & Circulatory - Other; Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan, Aichi Nagoya, Aichi, Japan
Japan, Ehime Matsuyama, Ehime, Japan
Japan, Fukui Yoshida-gun, Fukui, Japan
Japan, Fukuoka Fukuoka, Japan
Japan, Gifu Gifu, Japan
Japan, Gunma Maebashi, Gunma, Japan
Japan, Hyogo Kobe, Hyogo, Japan
Japan, Kanagawa Isehara, Kanagawa, Japan
Japan, Miyagi Sendai, Miyagi, Japan
Japan, Okayama Okayama, Japan
Japan, Osaka Osaka, Japan
Japan, Tokyo Shinagawa, Tokyo, Japan
United States of America, CA Duarte, CA, United States of America, 91010
United States of America, FL Pembroke Pines, FL, United States of America, 33028
United States of America, NY New York, NY, United States of America, 10016